Combination antifungal therapy for invasive aspergillosis - Is it indicated?

Medical Mycology

Volumn 44, Issue SUPPL. 1, 2006, Pages 373-382

  Steinbach, William J ^a  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antifungal; Aspergillosis; Aspergillus; Combination; Therapy

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANTIFUNGAL AGENT; CASPOFUNGIN; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; MICAFUNGIN; NIKKOMYCIN Z; POSACONAZOLE; RAVUCONAZOLE; RIFAMPICIN; TERBINAFINE; VORICONAZOLE;

ARTICLE; ASPERGILLOSIS; CANCER; CLINICAL STUDY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DATA ANALYSIS; DRUG ANTAGONISM; DRUG CHOICE; DRUG INDICATION; DRUG PENETRATION; DRUG POTENTIATION; DRUG TARGETING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VITRO STUDY; NEUTROPENIA; NONHUMAN; PATIENT CARE; PUBLISHING; RISK BENEFIT ANALYSIS; SALVAGE THERAPY; SYSTEMIC MYCOSIS; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ANIMALIA; ASPERGILLUS;

EID: 33749528153     PISSN: 13693786     EISSN: 14602709     Source Type: Journal    
DOI: 10.1080/13693780600860953     Document Type: Article

References (50)

1. Groll, AH and Shah, PM and Mentzel, C and (1996) Trends in postmortem epidemiology of invasive fungal infections at a university hospital J Infect, 33, pp. 23-32.
2. Patterson, TF and Kirkpatrick, WR and White, M and (2000) Invasive aspergillosis: Disease spectrum, treatment practices, and outcomes Medicine (Baltimore), 79, pp. 250-260.
3. Denning, DW and Marinus, A and Cohen, J and (1998) An EORTC multicentre prospective survey of invasive aspergillosis in haematological patients: diagnosis and therapeutic outcome J Infect, 37, pp. 173-180.
4. Steinbach, WJ and Stevens, DA. (2003) Review of newer antifungal and immunomodulatory strategies for invasive aspergillosis Clin Infect Dis, 37(suppl 3), pp. S157-87.
5. Bennett, JE and Dismukes, WE and Duma, RJ and (1979) A comparison of amphotericin B alone and combined with flucytosine in the treatment of cryptococcal meningitis N Engl J Med, 301, pp. 126-128.
6. Polak, A. (1999) The past, present, and future of antimycotic combination therapy Mycoses, 42, pp. 355-370.
7. Lewis, RE and Klepser, ME and Pfaller, MA. (1999) Combination systemic antifungal therapy for cryptococcosis, candidiasis, and aspergillosis J Infect Dis Pharmacotherapy, 3, pp. 61-83.
8. Popp, AI and White, MH and Quadri, T and Walshe, L and Armstrong, D. (1999) Amphotericin B with and without itraconazole for invasive aspergillosis: A three-year retrospective study Int J Infect Dis, 3, pp. 157-160.
9. Denning, DW and Stevens, DA. (1990) Antifungal and surgical treatment of invasive aspergillosis: Review of 2,121 published cases Rev Infect Dis, 12, pp. 1147-1200.
10. Verweij, PE and Donnelly, JP and Kullberg, BJ and Meis, JFGM and De Pauw, BE. (1994) Amphotericin B versus amphotericin B plus 5-flucytosine: Poor results in the treatment of proven systemic mycoses in neutropenic patients Infection, 22, pp. 81-85.
11. Stevens, DA and Kan, VL and Judson, MA and (2000) Practice guidelines for diseases caused by Aspergillus Clin Infect Dis, 30, pp. 696-709.
12. Steinbach, WJ and Stevens, DA and Denning, DW. (2003) Combination and sequential antifungal therapy for invasive aspergillosis: Review of published in vitro and in vivo interactions and 6281 clinical cases from 1966-2001 Clin Infect Dis, 37(suppl 3), pp. S188-224.
13. Denning, DW. (1996) Therapeutic outcome in invasive aspergillosis Clin Infect Dis, 23, pp. 608-615.
14. Lin, S-J and Schranz, J and Teutsch, SM. (2000) Aspergillosis case-fatality rate: Systemic review of the literature Clin Infect Dis, 32, pp. 358-366.
15. Schimpff, S and Satterlee, W and Young, VM and Serpick, A. (1971) Empiric therapy with carbenicillin and gentamicin for febrile patients with cancer and granulocytopenia N Engl J Med, 284, pp. 1061-1065.
16. Lewis, RE and Kontoyiannis, DP. (2001) Rationale for combination antifungal therapy Pharmacotherapy, 21, pp. 149S-164S.
17. Herbrecht, R and Denning, DW and Patterson, TF and (2002) Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis N Engl J Med, 347, pp. 408-415.
18. Denning, DW and Ribaud, P and Milpied, N and (2002) Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis Clin Infect Dis, 34, pp. 563-571.
19. Mosquera, J and Sharp, A and Moore, CB and Warn, PA and Denning, DW. (2002) In vitro interaction of terbinafine with itraconazole, fluconazole, amphotericin B and 5-flucytosine against Aspergillus spp J Antimicrob Chemother, 50, pp. 189-194.
20. Hosseini-Yeganeh, M and McLachlan, AJ. (2002) Physiologically based pharmacokinetic model for terbinafine in rats and humans Antimicrob Agents Chemother, 46, pp. 2219-2228.
21. LewisRE, SinghN, LimayeA,. Detection of synergy by XTT-enhanced checkerboard dilution testing of Aspergillus: Correlation with outcome in patients with invasive aspergillosis treated with combination voriconazole and caspofungin therapy. In:PRoceedings of the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy; December16-19, 2005; WashingtonDC: 2005.
22. Graybill, JR and Bocanegra, R and Gonzalez, GM and Najvar, LK. (2003) Combination antifungal therapy of murine aspergillosis: Liposomal amphotericin B and micafungin J Antimicrob Chemother, 52, pp. 656-662.
23. Clemons, KV and Stevens, DA. (2006) Efficacy of micafungin alone or in combination against experimental pulmonary aspergillosis Med Mycol, 44, pp. 69-73.
24. Capilla Luque, J and Clemons, KV and Stevens, DA. (2003) Efficacy of micafungin alone or in combination against systemic murine aspergillosis Antimicrob Agents Chemother, 47, pp. 1452-1455.
25. Kirkpatrick, WR and Perea, S and Coco, BJ and Patterson, TF. (2002) Efficacy of caspofungin alone and in combination with voriconazole in a guinea pig model of invasive aspergillosis Antimicrob Agents Chemother, 46, pp. 2564-2568.
26. MacCallum, DM and Whyte, JA and Odds, FC. (2005) Efficacy of caspofungin and voriconazole combinations in experimental aspergillosis Antimicrob Agents Chemother, 49, pp. 3697-3701.
27. Bowman, JC and Abruzzo, GK and Anderson, JW and (2001) Quantitative PCR assay to measure Aspergillus fumigatus burden in a murine model of disseminated aspergillosis: Demonstration of efficacy of caspofungin acetate Antimicrob Agents Chemother, 45, pp. 3474-3481.
28. Singh, G and Imai, J and Clemons, KV and Stevens, DA. (2005) Efficacy of caspofungin against central nervous system Aspergillus fumigatus infection in mice determined by TaqMan PCR and CFU methods Antimicrob Agents Chemother, 49, pp. 1369-1376.
29. Chandrasekar, PH and Cutright, JL and Manavathu, EK. (2004) Efficacy of voriconazole plus amphotericin B or micafungin in a guinea-pig model of invasive pulmonary aspergillosis Clin Microbiol Infect, 10, pp. 925-928.
30. Petraitis, V and Petraitiene, R and Sarafandi, AA and (2003) Combination therapy in treatment of experimental pulmonary aspergillosis: synergistic interaction between an antifungal triazole and an echinocandin J Infect Dis, 187, pp. 1834-1843.
31. Clemons, KV and Espiritu, M and Parmar, R and Stevens, DA. (2005) Comparative efficacies of conventional amphotericin B, liposomal amphotericin B (AmBisome), caspofungin, micafungin, and voriconazole alone and in combination against experimental murine central nervous system aspergillosis Antimicrob Agents Chemother, 49, pp. 4867-4875.
32. Najvar, LK and Cacciapuoti, A and Hernandez, S and (2004) Activity of posaconazole combined with amphotericin B against Aspergillus flavus infection in mice: Comparative studies in two laboratories Antimicrob Agents Chemother, 48, pp. 758-764.
33. GavaldaJ, LopezP, MartinMT, Evaluation of combination of voriconazole+ Terbinafine in the treatment of experimental pulmonary aspergillosis. In:PRogram and Abstracts of the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy; Oct 30-Nov 2, 2004; WashingtonDC: 2004.
34. Kirkpatrick, WR and Vallor, AC and McAtee, RK and (2005) Combination therapy with terbinafine and amphotericin B in a rabbit model of experimental invasive aspergillosis Antimicrob Agents Chemother, 49, pp. 4751-4753.
35. Dennis, CG and Greco, WR and Brun, Y and (2006) Effect of amphotericin B and micafungin combination on survival, histopathology, and fungal burden in experimental aspergillosis in the p47 phox-/- mouse model of chronic granulomatous disease Antimicrob Agents Chemother, 50, pp. 422-427.
36. Imai, J and Singh, G and Fernandez, B and Clemons, KV and Stevens, DA. (2005) Efficacy of abelcet and caspofungin, alone or in combinatioin, against CNS aspergillosis in a murine model J Antimicrob Chemother, 56, pp. 166-171.
37. Sionov, E and Mendlovic, S and Segai, E. (2005) Experimental systemic murine aspergillosis: Treatment with polyene and caspofungin combination and G-CSF J Antimicrob Chemother, 56, pp. 594-597.
38. Perea, S and Gonzalez, G and Fothergill, A and (2002) In vitro interaction of caspofungin acetate with voriconazole against clinical isolates of Aspergillus spp Antimicrob Agents Chemother, 4, pp. 3039-3041.
39. Marr, KA and Boeckh, M and Carter, RA and Kim, HW and Corey, L. (2004) Combination antifungal therapy for invasive aspergillosis Clin Infect Dis, 39, pp. 797-802.
40. Viscoli, C. (2004) Combination therapy for invasive aspergillosis Clin Infect Dis, 39, pp. 803-805.
41. Cesaro, S and Visintin, G. (2005) Combination antifungal therapy for invasive aspergillosis Clin Infect Dis, 40, pp. 1073-1076.
42. Kontoyannis, DP and Boktour, M and Hanna, H and (2005) Itraconazole added to a lipid formulation of amphotericin B does not improve outcome of primary treatment of invasive aspergillosis Cancer, 103, pp. 2334-2337.
43. Kontoyannis, DP and Hachem, R and Lewis, RE and (2003) Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignancies Cancer, 98, pp. 292-9.
44. RaadII, BoktourMR, HannaHA, KontoyannisDP, HachemRY. Posaconazole compared to amphotericin B lipid formulations in combination with caspofungin as salvage therapy for invasive aspergillosis in patients with hematologic malignancy. In:PRogram and Abstracts of the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy; Oct 30-Nov 2, 2004; WashingtonDC: 2004.
45. MunozLS, RuthazerR, BoucherH,. Combination antifungals for primary treatment oR invasive aspergillosis: Do they work?In:Program and Abstracts of the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy; Oct 30-Nov 2, 2004; WashingtonDC: 2004.
46. SinghN, LimayeA, SafdarN,. Combination of voriconazole and caspofungin as primary therapy for invasive aspergillosis in solid organ transplant recipients. In:PRoceedings of the 45th International Conference on Antimicrobial Agents and Chemotherapy; December 16-19, 2005; WashingtonDC: American Society for Microbiology; 2005.
47. Elanjikal, Z and Sorensen, J and Schmidt, H and (2003) Combination therapy with caspofungin and liposomal amphotericin B for invasive aspergillosis Pediatr. Infect. Dis. J., 22, pp. 653-656.
48. Damaj, G and Ivanov, V and LeBrigand, B and (2003) Rapid improvement of disseminated aspergillosis with caspofungin/voriconazole combination in an adult leukemic patient Annals of Hematology, 83, pp. 390-393.
49. Wheat, LJ. (2003) Combination therapy for aspergillosis: Is it needed, and which combination? J Infect Dis, 187, pp. 1831-3.
50. Bennett, JE and Powers, J and de Pauw, B and (2003) Forum report: Issues in the design of trials of drugs for the treatment of invasive aspergillosis Clin Infect Dis, 36(suppl 3), pp. S113-6.